

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

GRANT OF SHARE OPTIONS

The Board announces that on August 27, 2021, a total of 4,748,142 Share Options were granted to certain eligible persons pursuant to the 2019 Equity Incentive Plan to subscribe for a total of 4,748,142 Shares. According to Rule 17.06A of the Listing Rules, details of the grant of Share Options are set out as follows:

1. Date of grant August 27, 2021
2. Number of grantees 151
3. Exercise price of the Share Options granted HK\$12.56. The exercise price of HK\$12.56 per Share represents the highest of (i) the closing price of HK\$12.56 per Share as stated in the daily quotation sheet issued by the Stock Exchange on the date of the grant; (ii) the average closing price of HK\$12.40 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five trading days immediately preceding the date of grant; and (iii) the nominal value of the Share, which is US\$0.0001.
4. Total number of the new Share Options granted 4,748,142 pursuant to the 2019 Equity Incentive Plan
5. Validity period of the Share Options 10 years from date of grant, i.e. from August 27, 2021 to August 26, 2031 (both days inclusive)
6. Vesting schedule of the Share Options (i) 30% of the Share Options shall be vested on the second anniversary of the date of grant; (ii) 30% of the Share Options shall be vested on the third anniversary of the date of grant; and (iii) the remaining 40% of the Share Options shall be vested on the fourth anniversary of the date of grant.

7. Among the total 4,748,142 Share Options, 1,800,000 Share Options are granted to Directors and chief executives with details as follows:

Name of grantee	Relationship with the Company	Number of Share Options granted
Jay Mei	Executive Director and Chief Executive Officer	1,000,000
Donald A. Lung	Executive Director and Chief Financial Officer	100,000
John F. Chin	Executive Director and Chief Business Officer	80,000
Kevin P. Lynch	Executive Director and Chief Medical Officer	300,000
Mark J. Alles	Independent non-Executive Director	50,000
Jing Qian	Independent non-Executive Director	10,000
Sheng Tang	Independent non-Executive Director	10,000
Bo Shan	Chief Scientific Officer	150,000
Yiteng Liu	Chief Operating Officer	100,000

In accordance with Rule 17.04(1) of the Listing Rules and the 2019 Equity Incentive Plan, the grant of the Share Options to the above Directors has been approved by the independent non-executive Directors. The grantees have also abstained from voting so far as the resolution for the approval of the grant of Share Options to the grantees concerned.

Save as disclosed above, none of the grantees is a Director, chief executive or substantial shareholder of the Company or an associate of any of them. The grant of the Share Options to the above grantees is not subject to approval by shareholders of the Company under Rule 17.04(1) of the Listing Rules.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following terms shall have the following meanings:

“2019 Equity Incentive Plan”	the 2019 equity incentive plan adopted by the Company on December 30, 2019 and amended by resolution of the Board on August 18, 2020
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of Directors
“Company”	Antengene Corporation Limited (德琪醫藥有限公司), an exempted company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange
“Director(s)”	director(s) of the Company
“HK\$”	Hong Kong dollar(s), the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China

“Listing Rules”	The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended from time to time
“Share(s)”	ordinary share(s) in the share capital of the Company with a par value of US\$0.0001 each
“Share Option(s)”	the share option(s) to be granted pursuant to the terms and conditions of the 2019 Equity Incentive Plan
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“substantial shareholder(s)”	has the meaning ascribed thereto under the Listing Rules
“US\$”	United States dollars, the lawful currency of the United States of America

By Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, August 27, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald A. Lung and Dr. Kevin P. Lynch as executive directors; Dr. Kan Chen and Mr. Yanling Cao as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.